Clinical trials: Oral Ulcer
Palatal Neoplasms, Lip Neoplasm
Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making
Objectives Validate the OncAlert® RAPID Test by demonstrating that NPV > (1 -prevalence). Evaluate the independent and associated contribution of readily available clinical variables including age, race, gender, HPV status…
- Conditions
- Palatal Neoplasms, Lip Neoplasm, Gingival Neoplasms, Leukoplakia, Oral
- Trial name
- NCT03239834
- Testing
- OncAlert
- Where
- 26 sites in United States
- Volunteers
- 893 people
- Sponsor
- Vigilant Biosciences, Inc.
Ulcerative Colitis
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
This is a Phase 1b, randomized, double-blind, multicenter dose-ranging study to evaluate the safety, tolerability, and PK of NX-13.
- Trial name
- NCT04862741
- Testing
- NX-13 250mg IR, NX-13 500mg IR, NX-13 500mg MR
- Where
- 31 sites in United States, Ukraine
- Volunteers
- 39 people
- Sponsor
- Landos Biopharma Inc.
Healthy
Safety and Efficacy Study of GB001 Recombinant Peptide Spray in Subjects With Mild Recurrent Aphthous Ulcers
This trial is conducted in China. The purpose is to evaluate the efficacy, Pharmacokinetics (PK) profile, immunogenicity and safety of GB001 recombinant peptide spray in adults with mild recurrent aphthous ulcer.
- Trial name
- NCT06429566
- Testing
- GB001 recombinant peptide spray low dose group、high dose group
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang Echon Biopharm Limited
Oral Mucositis
Study for the Prevention of Oral Mucositis (SPOM)
1. Study Design Prospective, Randomized, Questionnaire-Based Study Study Type: Phase 1/Phase 2 Interventional Clinical Trial Intervention Model: Parallel Assignment Masking: None (Open-label) Actual Enrollment: 100 participants…
- Trial name
- SPOM (NCT05338398)
- Testing
- Bocaliner, Benzydamine
- Where
- Armenia
- Volunteers
- 100 people
- Sponsor
- E2Bio Life Sciences, LLC
Ulcerative Colitis
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers
This is a Phase 1, first in human, three-part randomized, double-blind, placebo-controlled dose escalation trial to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of EQ504 following single…
- Trial name
- NCT07869225
- Testing
- EQ504
- Where
- Australia
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Equillium
Ulcerative Colitis
Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)
To evaluate the percentage of subjects with clinical recurrence of UC at 6 months using MMX mesalamine once daily.
- Trial name
- NCT00446849
- Testing
- MMX Mesalamine
- Where
- 62 sites in United States
- Volunteers
- 290 people
- Sponsor
- Shire
Canker Sore
Luminance RED for Canker Sores
Canker sores, also called aphthous ulcers, are small, shallow lesions that develop on the soft tissues in your mouth or at the base of your gums.
- Trial name
- NCT04914533
- Testing
- Luminance RED Low Level Laser Therapy Device
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- ProofPilot
Ulcerative Colitis
Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- NCT05570006
- Testing
- ABBV-668
- Where
- 30 sites in United States, Belgium and 2 more
- Volunteers
- 30 people
- Sponsor
- AbbVie
Ulcerative Colitis
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
Phase 2 induction study with a long-term extension (LTE) period in participants with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT05785715
- Testing
- NX-13 250mg, NX-13 750mg
- Where
- 35 sites in United States, Belgium and 2 more
- Volunteers
- 81 people
- Sponsor
- AbbVie
Ulcerative Colitis
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well…
- Trial name
- NCT06254950
- Testing
- TAK-279
- Where
- 141 sites in United States, Australia and 20 more
- Volunteers
- 213 people
- Sponsor
- Takeda